Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (9), 1160-1168
- https://doi.org/10.1016/j.annonc.2020.05.024
Abstract
No abstract availableFunding Information
- Servier
- Taiho
This publication has 16 references indexed in Scilit:
- Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancersFuture Oncology, 2018
- The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancerEuropean Journal of Cancer, 2018
- Trifluridine/tipiracil in metastatic colorectal cancer: a guide to its useDrugs & Therapy Perspectives, 2017
- Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trialESMO Open, 2017
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology, 2016
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2015
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialThe Lancet Oncology, 2013
- TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialThe Lancet Oncology, 2012
- Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin CAnnals of Oncology, 2012
- Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyJournal of Clinical Oncology, 2010